|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||
  Journal of Gastroenterology and HepatologyVolume 15 Issue 10, Pages 1120 - 1124 Published Online: 7 Jul 2008 Journal compilation © 2010 Blackwell Publishing Asia Pty Ltd and Journal of Gastroenterology and Hepatology Foundation Published in partnership with the Journal of Gastroenterology and Hepatology Foundation
Abstract | References | Full Text: HTML, PDF (Size: 89K) | Related Articles | Citation Tracking  Vasoactive intestinal polypeptide appears to be one of the mediators in misoprostol-enhanced small intestinal transit in rats Copyright Blackwell Science Asia Pty. Ltd. KEYWORDS gastrointestinal motility • misoprostol • prostaglandin • small intestinal transit • vasoactive intestinal polypeptide ABSTRACTBackground and Aims:Prostaglandin analogs have the pharmacologic effect of speeding up small intestinal transit (SIT). It remains unknown whether some gut peptides also mediate this enhancement. We studied the effect of misoprostol on rat SIT and looked at the role of vasoactive intestinal polypeptide (VIP) release during its action. Methods:A group of rats initially received oral misoprostol treatment of 1, 10, 50 and 100 μg/kg, respectively. By using orally fed charcoal as a motility marker, the SIT was assessed at 30 min following oral misoprostol treatment. Another group of rats received misoprostol as an intraperitoneal injection in similar doses to the group above. The small intestinal transit was computed for this group at 30 min following misoprostol injection via an instilled radiochromium motility marker that went through a previously placed intraduodenal catheter. The plasma VIP level was measured by using a radioimmunoassay kit. Results:Neither charcoal evaluated transit nor the plasma VIP level was influenced by the lower doses of oral misoprostol treatment (1 and 10 μg/kg), whereas other doses enhanced SIT and diminished the plasma VIP level (P < 0.01). The similar effects on radiochromium computed SIT (P < 0.01) and plasma VIP levels were obtained in tubed rats following misoprostol intraperitoneal treatment. The SIT results correlated negatively with plasma VIP levels. Conclusions:Enhanced SIT and diminished VIP levels are found in rats following misoprostol treatment. It appears that inhibited VIP release is one of the mechanisms in misoprostol-enhanced SIT.
| 
|
